HomeCompareCRXTQ vs GBDC

CRXTQ vs GBDC: Dividend Comparison 2026

CRXTQ yields 142857.14% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CRXTQ wins by $1.703105290929614e+28M in total portfolio value
10 years
CRXTQ
CRXTQ
● Live price
142857.14%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.703105290929614e+28M
Annual income
$17,007,633,297,048,937,000,000,000,000,000,000.00
Full CRXTQ calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — CRXTQ vs GBDC

📍 CRXTQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRXTQGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRXTQ + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CRXTQ pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRXTQ
Annual income on $10K today (after 15% tax)
$12,142,857.14/yr
After 10yr DRIP, annual income (after tax)
$14,456,488,302,491,595,000,000,000,000,000,000.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, CRXTQ beats the other by $14,456,488,302,491,595,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRXTQ + GBDC for your $10,000?

CRXTQ: 50%GBDC: 50%
100% GBDC50/50100% CRXTQ
Portfolio after 10yr
$8.51552645464807e+27M
Annual income
$8,503,816,648,524,468,000,000,000,000,000,000.00/yr
Blended yield
99.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

CRXTQ
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRXTQ buys
0
GBDC buys
0
No recent congressional trades found for CRXTQ or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRXTQGBDC
Forward yield142857.14%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$1.703105290929614e+28M$20.78M
Annual income after 10y$17,007,633,297,048,937,000,000,000,000,000,000.00$16,389,263.41
Total dividends collected$1.70295189426983e+28M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy

Year-by-year: CRXTQ vs GBDC ($10,000, DRIP)

YearCRXTQ PortfolioCRXTQ Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$14,296,414$14,285,714.29$12,490$1,790.28+$14.28MCRXTQ
2$19,102,632,658$19,087,335,494.95$16,522$3,157.73+$19102.62MCRXTQ
3$23,856,124,353,624$23,835,684,536,679.88$23,578$5,898.68+$23856124.33MCRXTQ
4$27,845,102,711,212,050$27,819,576,658,153,670.00$37,115$11,886.75+$27845102711.17MCRXTQ
5$30,376,787,884,694,190,000$30,346,993,624,793,194,000.00$66,136$26,423.57+$30376787884694.12MCRXTQ
6$30,972,831,647,170,750,000,000$30,940,328,484,134,132,000,000.00$137,257$66,491.44+$30972831647170752.00MCRXTQ
7$29,516,720,240,819,920,000,000,000$29,483,579,310,957,454,000,000,000.00$341,734$194,868.54+$29516720240819920896.00MCRXTQ
8$26,290,911,335,300,946,000,000,000,000$26,259,328,444,643,270,000,000,000,000.00$1,050,788$685,133.02+$2.6290911335300947e+22MCRXTQ
9$21,887,488,081,496,375,000,000,000,000,000$21,859,356,806,367,600,000,000,000,000,000.00$4,099,314$2,974,971.01+$2.1887488081496375e+25MCRXTQ
10$17,031,052,909,296,140,000,000,000,000,000,000$17,007,633,297,048,937,000,000,000,000,000,000.00$20,775,530$16,389,263.41+$1.703105290929614e+28MCRXTQ

CRXTQ vs GBDC: Complete Analysis 2026

CRXTQStock

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois. On September 5, 2022, Clarus Therapeutics Holdings, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full CRXTQ Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this CRXTQ vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRXTQ vs SCHDCRXTQ vs JEPICRXTQ vs OCRXTQ vs KOCRXTQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.